|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Weatherspoon DJ, Chattopadhyay A,
Boroumand S and Garcia I: Oral cavity and oropharyngeal cancer
incidence trends and disparities in the United States: 2000-2010.
Cancer Epidemiol. 39:497–504. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rusthoven K, Ballonoff A, Raben D and Chen
C: Poor prognosis in patients with stage I and II oral tongue
squamous cell carcinoma. Cancer. 112:345–351. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
St John MA, Abemayor E and Wong DT: Recent
new approaches to the treatment of head and neck cancer. Anticancer
Drugs. 17:365–375. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yan D, Cai X and Feng Y: miR-183 modulates
cell apoptosis and proliferation in tongue squamous cell carcinoma
SCC25 cell line. Oncol Res. 24:399–404. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Isayeva T, Brandwein-Gensler M, Somarathna
M, Moore-Smith LD and Lee T: Micro-RNA profiling as a predictor of
clinical outcomes for head and neck cancer patients. Curr Pharm
Des. 23:4729–4744. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shi B, Yan W, Liu G and Guo Y:
MicroRNA-488 inhibits tongue squamous carcinoma cell invasion and
EMT by directly targeting ATF3. Cell Mol Biol Lett.
23(28)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pardini B, De Maria D, Francavilla A, Di
Gaetano C, Ronco G and Naccarati A: MicroRNAs as markers of
progression in cervical cancer: A systematic review. BMC Cancer.
18(696)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Arndt GM, Dossey L, Cullen LM, Lai A,
Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, et al:
Characterization of global microRNA expression reveals oncogenic
potential of miR-145 in metastatic colorectal cancer. BMC Cancer.
9(374)2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zaman MS, Chen Y, Deng G, Shahryari V, Suh
SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, et al: The
functional significance of microRNA-145 in prostate cancer. Br J
Cancer. 103:256–264. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ye D, Shen Z and Zhou S: Function of
microRNA-145 and mechanisms underlying its role in malignant tumor
diagnosis and treatment. Cancer Manag Res. 11:969–979.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Karatas OF, Oner M, Abay A and Diyapoglu
A: MicroRNAs in human tongue squamous cell carcinoma: From
pathogenesis to therapeutic implications. Oral Oncol. 67:124–130.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Harding RL and Velleman SG: MicroRNA
regulation of myogenic satellite cell proliferation and
differentiation. Mol Cell Biochem. 412:181–195. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhou X, Yue Y, Wang R, Gong B and Duan Z:
MicroRNA-145 inhibits tumorigenesis and invasion of cervical cancer
stem cells. Int J Oncol. 50:853–862. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shen X, Jiang H, Chen Z, Lu B, Zhu Y, Mao
J, Chai K and Chen W: MicroRNA-145 inhibits cell migration and
invasion in colorectal cancer by targeting TWIST. OncoTargets Ther.
12:10799–10809. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liu Q, Chen J, Wang B, Zheng Y, Wan Y,
Wang Y, Zhou L, Liu S, Li G and Yan Y: miR-145 modulates
epithelial-mesenchymal transition and invasion by targeting ZEB2 in
non-small cell lung cancer cell lines. J Cell Biochem.
2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xia F, Xiong Y and Li Q: Interaction of
lincRNA ROR and p53/miR-145 correlates with lung cancer stem cell
signatures. J Cell Biochem: May 18, 2017. https://doi.org/10.1002/jcb.25960.
|
|
23
|
Wei H, Wen-Ming C and Jun-Bo J: Plasma
miR-145 as a novel biomarker for the diagnosis and radiosensitivity
prediction of human cervical cancer. J Int Med Res. 45:1054–1060.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tabrizi M, Khalili M, Vasei M, Nouraei N,
Mansour Samaei N, Khavanin A, Khajehei M and Mowla SJ: Evaluating
the miR-302b and miR-145 expression in formalin-fixed
paraffin-embedded samples of esophageal squamous cell carcinoma.
Arch Iran Med. 18:173–178. 2015.PubMed/NCBI
|
|
25
|
Sheng N, Tan G, You W, Chen H, Gong J,
Chen D, Zhang H and Wang Z: MiR-145 inhibits human colorectal
cancer cell migration and invasion via PAK4-dependent pathway.
Cancer Med. 6:1331–1340. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mei LL, Wang WJ, Qiu YT, Xie XF, Bai J and
Shi ZZ: miR-145-5p suppresses tumor cell migration, invasion and
epithelial to mesenchymal transition by regulating the Sp1/NF-κB
signaling pathway in esophageal squamous cell carcinoma. Int J Mol
Sci. 18(18)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Han Q, Zhang HY, Zhong BL, Wang XJ, Zhang
B and Chen H: MicroRNA-145 inhibits cell migration and invasion and
regulates epithelial-mesenchymal transition (EMT) by targeting
connective tissue growth factor (CTGF) in esophageal squamous cell
carcinoma. Med Sci Monit. 22:3925–3934. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jin C, Wang A, Liu L, Wang G, Li G and Han
Z: miR-145-5p inhibits tumor occurrence and metastasis through the
NF-κB signaling pathway by targeting TLR4 in malignant melanoma. J
Cell Biochem. 120:11115–11126. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kliese N, Gobrecht P, Pachow D, Andrae N,
Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F,
Reifenberger G, Riemenschneider MJ, et al: miRNA-145 is
downregulated in atypical and anaplastic meningiomas and negatively
regulates motility and proliferation of meningioma cells. Oncogene.
32:4712–4720. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yang C, Xia Z, Zhu L, Li Y, Zheng Z, Liang
J and Wu L: MicroRNA-139-5p modulates the growth and metastasis of
malignant melanoma cells via the PI3K/AKT signaling pathway by
binding to IGF1R. Cell Cycle. 18:3513–3524. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shi X, Wang J, Lei Y, Cong C, Tan D and
Zhou X: Research progress on the PI3K/AKT signaling pathway in
gynecological cancer (Review). Mol Med Rep. 19:4529–4535.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhu X and Zhu R: Curcumin suppresses the
progression of laryngeal squamous cell carcinoma through the
upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR
pathway. OncoTargets Ther. 11:3521–3531. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu S, Gao G, Yan D, Chen X, Yao X, Guo S,
Li G and Zhao Y: Effects of miR-145-5p through NRAS on the cell
proliferation, apoptosis, migration, and invasion in melanoma by
inhibiting MAPK and PI3K/AKT pathways. Cancer Med. 6:819–833.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li B, Ding CM, Li YX, Peng JC, Geng N and
Qin WW: MicroRNA-145 inhibits migration and induces apoptosis in
human non-small cell lung cancer cells through regulation of the
EGFR/PI3K/AKT signaling pathway. Oncol Rep. 40:2944–2954.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cheng Z, Dai LL, Wang X, Jia LQ, Jing XG,
Li PF, Liu M, Wang H and An L: MicroRNA-145 down-regulates mucin
5AC to alleviate airway remodeling and targets EGFR to inhibit
cytokine expression. Oncotarget. 8:46312–46325. 2017.PubMed/NCBI View Article : Google Scholar
|
